Acotec Scientific Holdings Limited (HKG:6669)

Market Cap	4.26B
Revenue (ttm)	649.64M
Net Income (ttm)	110.56M
Shares Out	313.39M
EPS (ttm)	0.36
PE Ratio	37.55
Forward PE	34.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,681,323
Average Volume	897,578
Open	12.39
Previous Close	12.30
Day's Range	12.27 - 13.96
52-Week Range	5.26 - 14.24
Beta	0.18
RSI	62.09
Earnings Date	Aug 22, 2025

About HKG:6669

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 650
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6669

Financial Performance

In 2024, HKG:6669's revenue was 533.99 million, an increase of 12.69% compared to the previous year's 473.85 million. Earnings were 52.28 million, an increase of 260.88%.

Financial numbers in CNY